Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Debra L. Wood"'
Autor:
Jordan Berlin, Anthony W. Tolcher, Cliff Ding, Jennifer G. Whisenant, Ivan D. Horak, Debra L. Wood, Paul I. Nadler, Ulla Holm Hansen, Johan Lantto, Niels Jørgen Ø. Skartved, Mikkel W. Pedersen, Amita Patnaik
Publikováno v:
Investigational New Drugs. 40:586-595
Autor:
Jordan, Berlin, Anthony W, Tolcher, Cliff, Ding, Jennifer G, Whisenant, Ivan D, Horak, Debra L, Wood, Paul I, Nadler, Ulla Holm, Hansen, Johan, Lantto, Niels Jørgen Ø, Skartved, Mikkel W, Pedersen, Amita, Patnaik
Publikováno v:
Investigational new drugs. 40(3)
Sym013 contains six humanized monoclonal antibodies that bind to non-overlapping epitopes on three human epidermal growth factor receptors (HER1-3). Preclinical studies suggested Sym013 strongly suppresses growth of multiple epithelial tumors. This i
Autor:
Gilles Tremblay, Jean-François Denis, Debra L. Wood, Nehal Lakhani, Daniel Vilarim Araujo, Timothy A. Yap, Tina Gruosso, Maureen D. O'Connor-McCourt, Ria Ghosh, Lilian Siu, Sandra Sinclair, Paul I. Nadler
Publikováno v:
Poster Presentations.
Background AVID200 is a rationally designed first-in-class receptor ectodomain trap that inhibits transforming growth factor-beta (TGF-beta) isoforms -beta1 and -beta3 with pM potency. TGF-beta signaling is highly immunosuppressive in the tumor micro
Autor:
Gilles Tremblay, Maureen O'Connor, Ria Ghosh, Daniel Vilarim Araujo, Jean-François Denis, Sreenivasa R Chandana, Lillian L. Siu, Manish Sharma, Timothy A. Yap, Paul I. Nadler, Tina Gruosso, Nehal Lakhani, Sandra Sinclair, Debra L. Wood, Jordi Rodon Ahnert
Publikováno v:
Journal of Clinical Oncology. 38:3587-3587
3587 Background: AVID200 is a rationally designed first-in-class, selective inhibitor of transforming growth factor-beta (TGF-beta) that neutralizes TGF-beta 1 & 3 with pM potency and 4,000 fold selectivity over TGF-beta 2. TGF-beta 1 & 3 signaling h
Autor:
Kyri Papadopoulos, Nehal Lakhani, Saad A. Khan, Debra L. Wood, Robert J. Lutz, Anthony W. Tolcher, Joyce O'Shaughnessy, Sandra Sinclair, Ria Ghosh, Karla Rivas, Sharon Wilks, Barbara Burtness, Paul I. Nadler, Jason M. Melear, Yvette Cole, Sree R Chandana
Publikováno v:
Molecular Cancer Therapeutics. 18:A088-A088
Background: Currently, no therapies are approved specifically for EGFR-overexpressing tumors. AVID100 is a novel anti-EGFR antibody drug conjugate (ADC, DM1 payload) that was rationally designed for anti-tumor efficacy without accompanying on-target,
Autor:
Sreenivasa R Chandana, Kyri Papadopoulos, Nehal Lakhani, Yvette Cole, Sandra Sinclair, Anthony W. Tolcher, Debra L. Wood, Paul I. Nadler, Karla Rivas
Publikováno v:
Cancer Research. 79:CT056-CT056
Background AVID100, a rationally designed anti-EGFR-DM1 conjugate, showed potent activity in preclinical models, including cancer cell lines resistant to approved anti-EGFR monoclonal antibodies. In addition, AVID100 showed increased toxicity on tumo
Autor:
Eric K. Rowinsky, George Hage, Paul I. Nadler, Amita Patnaik, Mark S. Huberman, Julie Wolf, Daniel D. Von Hoff, Tomislav Dragovich, Marta Hamilton, Debra L. Wood
Publikováno v:
Cancer Chemotherapy and Pharmacology. 60:295-303
The purpose of this phase IB trial was to evaluate the tolerability, pharmacokinetics and preliminary evidence of antitumor activity of erlotinib plus gemcitabine in patients with pancreatic cancer and other solid tumors.Patients included those with
Autor:
Andrew H. Ko, E. Gabriela Chiorean, Eunice Lee Kwak, Heinz-Josef Lenz, Paul I. Nadler, Debra L. Wood, Masamoto Fujimori, Tetsuhi Inada, Hiroyuki Kouji, Robert R. McWilliams
Publikováno v:
Journal of Clinical Oncology. 34:e15721-e15721
Autor:
C. Puccio, Nancy Coombe, Zalmen A. Arlin, Abraham Mittelman, Debra L. Wood, Brinj Singh, Gafney E, Tauseef Ahmed, Paul I. Nadler
Publikováno v:
Investigational New Drugs. 10:183-190
Nineteen patients with advanced cancer were entered into a phase I clinical trial of Tumor Necrosis Factor (TNF) which was designed to determine the pharmacokinetic profile, safety, and maximal tolerated dose (MTD) of the recombinant human cytokine i
Autor:
Kohei Morita, Debra L. Wood, Tetsuhi Inada, Hiroyuki Kouji, Eunice L. Kwak, Andrew H. Ko, Heinz-Josef Lenz, Masamoto Fujimori, Robert R. McWilliams, E. Gabriela Chiorean, Paul I. Nadler
Publikováno v:
Journal of Clinical Oncology. 33:e15270-e15270
e15270 Background: PRI-724 is a first-in-class cAMP-response element-binding protein (CBP)/β-catenin modulator that induces stem cell differentiation. In pre-clinical models, PRI-724 increases p300...